UK prescribing
This article was originally published in The Tan Sheet
Executive Summary
The British Medical Association has called for an "urgent meeting" with British Health Secretary Patricia Hewitt following the UK's announcement to grant prescribing powers to nurses and pharmacists. Hewitt said Nov. 10 that nurses and pharmacists will be afforded prescribing rights for any medical condition, excluding controlled drugs, beginning in Spring 2006 if they complete additional training (1"The Tan Sheet" Nov. 21, 2005, In Brief). "It is difficult to see how healthcare professionals who are not trained to diagnose disease can safely prescribe appropriate treatment," BMA Chairman James Johnson states in a release. Central Consultants & Specialists Committee Chairman Paul Miller called the decision an "irresponsible and dangerous move. Patients will suffer. I would not have me or my family subject to anything other than the highest level of care and prescribing, which is that provided by a fully trained doctor"...
You may also be interested in...
UK prescribing rights
Pharmacists and nurses in the UK have been granted the ability to prescribe any licensed medication for any medical condition, except for controlled drugs, beginning in Spring 2006, British Health Secretary Patricia Hewitt announces Nov. 10. Nurses and pharmacists would be required to undergo training and registration to gain prescribing privileges, the Department of Health states. "By expanding traditional prescribing roles, patients can more easily access the medicines they need from an increased number of highly trained health professionals," Hewitt states. The Medicines & Healthcare products Regulatory Agency requested comments on extended prescribing rights in March (1"The Tan Sheet" March 14, 2005, p. 17)...
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.